GT Biopharma, Inc. reports material agreement in SEC 8-K

GT Biopharma, Inc. filed an 8-K covering a material definitive agreement, an unregistered sale of equity securities, SEC Item 3.03, and charter, bylaw or fiscal-year changes. Nelo verified the filing topics against the primary SEC document. This is a company disclosure filed with the SEC, not an SEC enforcement action.